Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives

James W Verbsky1, William J Grossman

  • 1Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA

Annals of Medicine
|February 2, 2006
PubMed

Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease in which the immune system becomes overactive due to its inability to effectively respond to infections and/or shut down the immune response to such infections. The discovery of genetic defects in the secretory pathway of natural killer (NK) cells and cytotoxic T cells in some patients with this disease has raised important questions of the role of cytotoxic cells in the control of infections and in immune regulation. This review will give a brief overview of the clinical presentation and accepted treatment of HLH. Furthermore, it will give an in-depth review into the known genetic defects and current knowledge of the pathophysiology of this disorder, and will highlight recent evidence suggesting that cytotoxic defects in CD4+ T regulatory cells may contribute to the pathogenesis of HLH.